Cargando…

Communicating trends in resistance using a drug resistance index

BACKGROUND: Antibiotic resistance is a growing problem worldwide, but communicating this challenge to policymakers and non-experts is complicated by the multiplicity of bacterial pathogens and the distinct classes of antibiotics used to treat them. It is difficult, even for experts aware of the phar...

Descripción completa

Detalles Bibliográficos
Autores principales: Laxminarayan, Ramanan, Klugman, Keith P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Group 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3221297/
https://www.ncbi.nlm.nih.gov/pubmed/22102636
http://dx.doi.org/10.1136/bmjopen-2011-000135
_version_ 1782217070679687168
author Laxminarayan, Ramanan
Klugman, Keith P
author_facet Laxminarayan, Ramanan
Klugman, Keith P
author_sort Laxminarayan, Ramanan
collection PubMed
description BACKGROUND: Antibiotic resistance is a growing problem worldwide, but communicating this challenge to policymakers and non-experts is complicated by the multiplicity of bacterial pathogens and the distinct classes of antibiotics used to treat them. It is difficult, even for experts aware of the pharmacodynamics of antibiotics, to infer the seriousness of resistance without information on how commonly the antibiotic is being used and whether alternative antibiotics are available. Difficulty in aggregating resistance to multiple drugs to assess trends poses a further challenge to quantifying and communicating changes in resistance over time and across locations. METHODS: We developed a method for aggregating bacterial resistance to multiple antibiotics, creating an index comparable to the composite economic indices that measure consumer prices and stock market values. The resulting drug resistance index (DRI) and various subindices show antibiotic resistance and consumption trends in the USA but can be applied at any geographical level. FINDINGS: The DRI based on use patterns in 1999 for Escherichia coli rose from 0.25 (95% CI 0.23 to 0.26) to 0.30 (95% CI 0.29 to 0.32) between 1999 and 2006. However, the adaptive DRI, which includes treatment of baseline resistant strains with alternative agents, climbed from 0.25 to 0.27 (95% CI 0.25 to 0.28) during that period. In contrast, both the static-use and the adaptive DRIs for Acinetobacter spp. rose from 0.41 (95% CI 0.4 to 0.42) to 0.48 (95% CI 0.46 to 0.49) between 1999 and 2006. INTERPRETATION: Divergence between the static-use and the adaptive-use DRIs for E coli reflects the ability of physicians to adapt to increasing resistance. However, antibiotic use patterns did not change much in response to growing resistance to Acinetobacter spp. because physicians were unable to adapt; new drugs for Acinetobacter spp. are therefore needed. Composite indices that aggregate resistance to various drugs can be useful for assessing changes in drug resistance across time and space.
format Online
Article
Text
id pubmed-3221297
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BMJ Group
record_format MEDLINE/PubMed
spelling pubmed-32212972011-12-01 Communicating trends in resistance using a drug resistance index Laxminarayan, Ramanan Klugman, Keith P BMJ Open Drugs and Medicines BACKGROUND: Antibiotic resistance is a growing problem worldwide, but communicating this challenge to policymakers and non-experts is complicated by the multiplicity of bacterial pathogens and the distinct classes of antibiotics used to treat them. It is difficult, even for experts aware of the pharmacodynamics of antibiotics, to infer the seriousness of resistance without information on how commonly the antibiotic is being used and whether alternative antibiotics are available. Difficulty in aggregating resistance to multiple drugs to assess trends poses a further challenge to quantifying and communicating changes in resistance over time and across locations. METHODS: We developed a method for aggregating bacterial resistance to multiple antibiotics, creating an index comparable to the composite economic indices that measure consumer prices and stock market values. The resulting drug resistance index (DRI) and various subindices show antibiotic resistance and consumption trends in the USA but can be applied at any geographical level. FINDINGS: The DRI based on use patterns in 1999 for Escherichia coli rose from 0.25 (95% CI 0.23 to 0.26) to 0.30 (95% CI 0.29 to 0.32) between 1999 and 2006. However, the adaptive DRI, which includes treatment of baseline resistant strains with alternative agents, climbed from 0.25 to 0.27 (95% CI 0.25 to 0.28) during that period. In contrast, both the static-use and the adaptive DRIs for Acinetobacter spp. rose from 0.41 (95% CI 0.4 to 0.42) to 0.48 (95% CI 0.46 to 0.49) between 1999 and 2006. INTERPRETATION: Divergence between the static-use and the adaptive-use DRIs for E coli reflects the ability of physicians to adapt to increasing resistance. However, antibiotic use patterns did not change much in response to growing resistance to Acinetobacter spp. because physicians were unable to adapt; new drugs for Acinetobacter spp. are therefore needed. Composite indices that aggregate resistance to various drugs can be useful for assessing changes in drug resistance across time and space. BMJ Group 2011-11-14 /pmc/articles/PMC3221297/ /pubmed/22102636 http://dx.doi.org/10.1136/bmjopen-2011-000135 Text en © 2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.
spellingShingle Drugs and Medicines
Laxminarayan, Ramanan
Klugman, Keith P
Communicating trends in resistance using a drug resistance index
title Communicating trends in resistance using a drug resistance index
title_full Communicating trends in resistance using a drug resistance index
title_fullStr Communicating trends in resistance using a drug resistance index
title_full_unstemmed Communicating trends in resistance using a drug resistance index
title_short Communicating trends in resistance using a drug resistance index
title_sort communicating trends in resistance using a drug resistance index
topic Drugs and Medicines
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3221297/
https://www.ncbi.nlm.nih.gov/pubmed/22102636
http://dx.doi.org/10.1136/bmjopen-2011-000135
work_keys_str_mv AT laxminarayanramanan communicatingtrendsinresistanceusingadrugresistanceindex
AT klugmankeithp communicatingtrendsinresistanceusingadrugresistanceindex